

health systems established COVID-19-only hospitals as the pandemic progressed, our strategy was informed by the ORTP planning tools, which helped to shape the early planning process.


When the first patient was hospitalized at BPH, HCWs were ready to care for that patient and were confident in their training. Having a cadre of nurses, respiratory therapists, and physicians trained in advance to care for patients with COVID-19 was critical in alleviating anxiety, which was expressed by many HCWs throughout the United States. Our model allowed safe care for patients and optimized HCW safety.

The advantages of this model were that PPE use was consolidated, and staff became adept at donning and doffing PPE correctly and identifying best practices to conserve PPE. Concentrating training among a core group of HCWs who then trained others allowed us to quickly train all needed personnel. Having most patients with COVID-19 in one facility allowed patient care protocols to be standardized, bolstered diagnostic and testing capabilities, and facilitated communication among staff.

The main disadvantages of this model of care were that we did not anticipate that patients in Michigan would not be allowed to be transferred to Ohio. This meant that we needed to rapidly duplicate our process in Michigan. Also, transferring critically ill patients at a time when rapid testing was not available meant that patients were transferred with suspected rather than confirmed illness.

Our experience suggests that a hospital dedicated entirely to a novel infection may be a useful strategy for healthcare systems in pandemic planning. This strategy should be considered by large health systems in their advanced planning for future pandemics.

Monthly trend in mortality and length of stay among coronavirus disease 2019 (COVID-19) patients: Analysis of a nationwide multihospital US database

Xiaozhou Fan PhD¹ , Barbara H. Johnson MBA¹, Stephen S. Johnston PhD¹, Nivesh Elangovanraaj BE², Prerna Kothari BTech², Avrum Spira MD, MSc³, Paul Coplan ScD, MBA¹ and Rahul Khanna PhD, MBA¹

¹Medical Device Epidemiology and Real-World Data Sciences, Johnson & Johnson, New Brunswick, New Jersey, United States, ²MuSigma, Inc, Bangalore, India and ³Lung Cancer Initiative, Johnson & Johnson, New Brunswick, New Jersey, United States

Since emerging in the first quarter of 2020, 33.6 million identified cases of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory coronavirus virus 2 (SARS-CoV-2) have been reported, including >603,000 associated deaths in the United States as of mid-July, 2021.¹ Recent evidence suggests that the case fatality rate has been declining among COVID-19 patients,^{2,3} with

Acknowledgments. We acknowledge all of the administrative and clinical care staff that made planning and patient care possible.

Financial support. No financial support was provided relevant to this article.

Conflicts of interest. Dr. Jennifer Hanrahan was Co-Chair of the Education Committee for the Outbreak Response Training Program. All other authors report no conflicts of interest relevant to this article.

References

1. Banach D, Johnston B, Al-Zubeid, D, *et al*. Outbreak response and incident management: SHEA guidance and resources for healthcare epidemiologists in US acute-care hospitals. *Infect Control Hosp Epidemiol* 2017; 38:1393–1419.
2. SHEA/CDC Outbreak Response Training Program (ORTP). Society for Healthcare Epidemiologists of America (SHEA) website. <https://learningce.shea-online.org/content/sheacdc-outbreak-response-training-program-ortp#group-tabs-node-course-default1/index.php>. Accessed November 7, 2020.
3. Outbreak response tool kits. SHEA/CDC Outbreak Response Training Program (ORTP) website. <https://ortp.guidelinecentral.com/>. Accessed November 7, 2020.
4. Jester BJ, Uyeki TM, Patel A, Koonin L, Jernigan DB. 100 Years of medical countermeasures and pandemic influenza preparedness. *Am J Public Health* 2018;108:1469–1472.
5. Wang X, Ferro EG, Zhou G, Hashimoto D, Bhatt DL. Association between universal masking in a healthcare system and SARS-CoV-2 positivity among healthcare workers. *JAMA* 2020;324:703–704.
6. Chen Y, Tong X, Wang J, *et al*. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. *J Infect* 2020;81:420–426.
7. Symptoms of coronavirus. Centers for Disease Control and Prevention website. <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>. Updated May 13, 2020. Accessed August 12, 2020.

one study reporting at least a 34% decline over a 3-month period among all age groups.² However, these studies have been restricted in their generalizability with samples limited to a single state² or health system.³

Methods

Using a nationwide, multihospital database, the Premier Healthcare Database (PHD),⁴ we identified patients with a diagnosis of COVID-19 (ICD-10-CM U07.1) admitted to an inpatient setting (ie, the first admission was considered the index admission). To be included, hospitals were required to provide continuous inpatient data from April 1, 2020 until July 31, 2020, to the PHD. We

Author for correspondence: Xiaozhou Fan, E-mail: xfan9@its.jnj.com

Cite this article: Fan X, *et al*. (2021). Monthly trend in mortality and length of stay among coronavirus disease 2019 (COVID-19) patients: Analysis of a nationwide multihospital US database. *Infection Control & Hospital Epidemiology*, 42: 1132–1135, <https://doi.org/10.1017/ice.2021.110>

© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.



Table 1. Patient Characteristics, Treatment, and Outcomes and Provider Characteristics Among COVID-19 Hospitalized Patients in April, May, June, or July

Characteristics	April	May	June	July	P Value ^a
	No. (%) / Mean (SD)	No. (%) / Mean (SD)	No. (%) / Mean (SD)	No. (%) / Mean (SD)	
Total No.	21,736	11,640	9,159	10,729	
Deceased, No. (%)	4,543 (20.9)	1552 (13.3)	853 (9.3)	825 (7.7)	<.0001
LOS, d (mean)	9.37 (10.12)	9.02 (9.56)	7.47 (7.22)	5.30 (4.31)	<.0001
Age y (continuous)	64.13 (17.05)	61.02 (19.28)	58.04 (19.36)	58.84 (19.19)	<.0001
Age y (categorical), no. (%)					
<18	107 (0.5)	158 (1.4)	93 (1.0)	132 (1.2)	
18–39	1,966 (9.0)	1,629 (14.0)	1,765 (19.3)	1,824 (17.0)	<.0001
40–49	2,075 (9.5)	1,294 (11.1)	1,134 (12.4)	1,323 (12.3)	
50–59	3,645 (16.8)	1,906 (16.4)	1,565 (17.1)	1,811 (16.9)	
60–69	5,029 (23.1)	2,307 (19.8)	1,676 (18.3)	2,110 (19.7)	
70–79	4,319 (19.9)	2,063 (17.7)	1,519 (16.6)	1,851 (17.3)	
80+	4,595 (21.1)	2,283 (19.6)	1,407 (15.4)	1,678 (15.6)	
Sex, no. (%)					
Male	11,656 (53.6)	5,843 (50.2)	4,501 (49.1)	5,282 (49.2)	<.0001
Female	10,080 (46.4)	5,797 (49.8)	4,658 (50.9)	5,447 (50.8)	
Race, no. (%)					
White	8,649 (39.8)	5,429 (46.6)	4,730 (51.6)	6,091 (56.8)	<.0001
African American	5,017 (23.1)	2,573 (22.1)	2,165 (23.6)	2,644 (24.6)	
Other/Unknown	8,070 (37.1)	3,638 (31.3)	2,264 (24.7)	1,994 (18.6)	
Payer, no. (%)					
Commercial	4,735 (21.8)	2,327 (20.0)	2,251 (24.6)	2,739 (25.5)	<.0001
Medicare	11,589 (53.3)	5,740 (49.3)	3,944 (43.1)	4,854 (45.2)	
Medicaid	4,020 (18.5)	2,472 (21.2)	1,603 (17.5)	1,661 (15.5)	
Other	1,392 (6.4)	1,101 (9.5)	1,361 (14.9)	1,475 (13.7)	
Marital status, no. (%)					
Single	11,867 (54.6)	6,602 (56.7)	4,937 (53.9)	5,609 (52.3)	<.0001
Married	8,089 (37.2)	3,996 (34.3)	3,658 (39.9)	4,611 (43.0)	
Other/Missing	1,780 (8.2)	1,042 (9.0)	564 (6.2)	509 (4.7)	
Elixhauser score (continuous), no. (%)	3.71 (2.27)	3.71 (2.40)	3.34 (2.30)	3.20 (2.16)	<.0001
Elixhauser score (categorical), no. (%)					
0	1,308 (6.0)	957 (8.2)	916 (10.0)	1,067 (9.9)	<.0001
1–2	5,816 (26.8)	3,007 (25.8)	2,773 (30.3)	3,369 (31.4)	
3–4	7,336 (33.8)	3,621 (31.1)	2,836 (31.0)	3,559 (33.2)	
≥5	7,276 (33.5)	4,055 (34.8)	2,634 (28.8)	2,734 (25.5)	
Hospital location, no. (%)					
Urban	20,636 (94.9)	10,892 (93.6)	8,469 (92.5)	9,527 (88.8)	<.0001
Rural	1,100 (5.1)	748 (6.4)	690 (7.5)	1,202 (11.2)	
No. of beds					
0–299	6,989 (32.2)	3,720 (32.0)	2,789 (30.5)	3,652 (34.0)	.0188
300–499	6,815 (31.4)	3,659 (31.4)	2,768 (30.2)	3,112 (29.0)	
≥500	7,932 (36.5)	4,261 (36.6)	3,602 (39.3)	3,965 (37.0)	
Teaching hospital, no. (%)					
No	8,103 (37.3)	5,270 (45.3)	4,722 (51.6)	5,971 (55.7)	<.0001
Yes	13,633 (62.7)	6,370 (54.7)	4,437 (48.4)	4,758 (44.3)	

(Continued)

Table 1. (Continued)

Characteristics	April	May	June	July	P Value ^a
	No. (%) / Mean (SD)	No. (%) / Mean (SD)	No. (%) / Mean (SD)	No. (%) / Mean (SD)	
Provider region, no. (%)					
Northeast	12,992 (59.8)	3,954 (34.0)	1,182 (12.9)	667 (6.2)	<.0001
Midwest	3,845 (17.7)	3,410 (29.3)	1,794 (19.6)	1,761 (16.4)	
West	515 (2.4)	311 (2.7)	505 (5.5)	611 (5.7)	
South	4,384 (20.2)	3,965 (34.1)	5,678 (62.0)	7,690 (71.7)	
Admission to ICU	5,139 (23.6)	2,966 (25.5)	2,214 (24.2)	2,006 (18.7)	<.0001
Mechanical ventilator	4,192 (19.3)	1,823 (15.7)	1,010 (11.0)	713 (6.6)	<.0001
Hydroxychloroquine	11,344 (52.2)	1,060 (9.1)	102 (1.1)	101 (0.9)	<.0001
Azithromycin	11,253 (51.8)	4,631 (39.8)	3,809 (41.6)	4,479 (41.7)	<.0001
Remdesivir	79 (0.4)	651 (5.6)	1,199 (13.1)	1,138 (10.6)	<.0001
convalescent plasma	339 (1.6)	359 (3.1)	285 (3.1)	250 (2.3)	<.0001
Anticoagulants	18,905 (87.0)	10,244 (88.0)	7,875 (86.0)	9,117 (85.0)	<.0001
Dexamethasone	1,032 (4.7)	958 (8.2)	3,143 (34.3)	6566 (61.2)	<.0001
Methylprednisolone	5,084 (23.4)	2,562 (22.0)	1,781 (19.4)	1,125 (10.5)	<.0001
Patients admitted to ICU, no.	5,139	2,966	2,214	2,006	
Deceased, no. (%)	2,095 (40.8)	976 (32.9)	605 (27.3)	545 (27.2)	<.0001
LOS, d (mean)	16.59 (14.20)	15.48 (12.75)	12.26 (9.29)	8.07 (5.66)	<.0001
Patients Aged under 18, no.	107	158	93	132	
Deceased, no. (%)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	.1727
LOS, d (mean)	6.69 (9.35)	5.25 (7.65)	4.30 (4.05)	3.08 (2.75)	<.0001
Patients aged 18–39 y, no.	1,966	1,629	1,765	1,824	
Deceased, no. (%)	58 (3.0)	23 (1.4)	16 (0.9)	21 (1.2)	<.0001
LOS, d (mean)	6.26 (8.34)	5.66 (7.60)	4.55 (4.41)	3.66 (3.17)	<.0001
Patients aged 40–49 y, no.	2075	1,294	1,134	1,323	
Deceased, no. (%)	128 (6.2)	67 (5.2)	43 (3.8)	35 (2.6)	<.0001
LOS, d (mean)	8.41 (10.23)	8.13 (9.36)	6.68 (6.67)	4.83 (3.62)	<.0001
Patients aged 50–59 y, no.	3,645	1,906	1,565	1,811	
Deceased, no. (%)	429 (11.8)	174 (9.1)	103 (6.6)	67 (3.7)	<.0001
LOS, d (mean)	9.94 (11.46)	9.68 (10.23)	7.78 (7.78)	5.35 (4.30)	<.0001
Patients aged 60–69 y, no.	5,029	2,307	1,676	2,110	
Deceased, no. (%)	967 (19.2)	360 (15.6)	176 (10.5)	177 (8.4)	<.0001
LOS, d (mean)	10.58 (10.91)	10.39 (10.38)	8.81 (7.94)	5.84 (4.60)	<.0001
Patients aged 70–79 y, no.	4,319	2,063	1,519	1,851	
Deceased, no. (%)	1,289 (29.8)	411 (19.9)	232 (15.3)	222 (12.0)	<.0001
LOS, d (mean)	9.93 (9.76)	10.63 (10.03)	8.86 (7.77)	6.08 (4.78)	<.0001
Patients aged ≥80 y, no.	4,595	2,283	1,407	1,678	
Deceased, no. (%)	1,671 (36.4)	517 (22.6)	283 (20.1)	303 (18.1)	<.0001
LOS, d (mean)	8.88 (8.63)	8.79 (8.35)	8.57 (7.26)	6.00 (4.49)	<.0001

Note. COVID-19, the novel coronavirus 2; SD, standard deviation; LOS, length of stay; ICU, Intensive care unit.

^aP values were based on Pearson's correlation tests for linear trend for continuous, ordinary, and dichotomous variables; and P values were based on χ^2 tests for nonordinary categorical variables (eg, race, payer, and marital status).

examined monthly trends (April 2020–July 2020) in mortality and length of stay (LOS) among the hospitalized patients. Then we assessed the relationship between admission month and study outcomes using a generalized estimating equations (GEE) model accounting for potential clustering of outcomes within hospitals,

and adjusting for patient characteristics (age, gender, race, marital status, and payer), comorbidity status (Elixhauser comorbidity index score), provider characteristics (region, number of beds, location, and teaching hospital or not), and treatments for COVID-19 (admit to intensive care unit, use of ventilators,

hydroxychloroquine, azithromycin, remdesivir, convalescent plasma, anticoagulants, dexamethasone, and methylprednisolone). Furthermore, we conducted a stratified GEE analysis according to age. Analyses were performed using R version 4.0.0 software (R Foundation for Statistical Computing, Vienna, Austria).

Results

The final sample included 53,264 COVID-19 patients from 302 hospitals in 4 geographic regions: 118 (39.1%) were admitted in the South, 104 (34.4%) in the Midwest, 62 (20.5%) in the Northeast, and 18 (6.0%) in the West. Furthermore, 21,736 were admitted in April; 11,640 were admitted in May; 9,159 were admitted in June; and 10,729 were admitted in July. The distributions of mortality rate, LOS, and covariates included in the GEE model by admission months in the overall study cohort, in patients admitted to ICU, and in each age group are shown in Table 1. The mean age of the patients decreased from 64.1 years (± 17.1) in April to 58.8 years (± 19.2) in July (P trend $< .0001$). The mean Elixhauser comorbidity index score,⁵ used to assess comorbidities among study patients, decreased from 3.7 (± 2.3) in April to 3.2 (± 2.2) in July (P trend $< .0001$), and the proportion of patients with an index score of 5 and above (indicating high underlying comorbidity burden) fell from 33.5% in April to 25.5% in July (P trend $< .0001$). The proportion of patients on mechanical ventilation decreased from 19.3% in April to 6.6% in July (P trend $< .0001$).

The mortality rate among hospitalized COVID-19 patients declined from 20.9% in April to 7.7% in July (P trend $< .0001$). The LOS also declined during this period, from 9.4 days (± 10.1) in April to 5.3 days (± 4.3) in July (P trend $< .0001$). Results from GEE analysis after accounting for the differences in the patient population by admission months indicate that COVID-19 patients admitted in May had 43% lower odds of mortality (odds ratio [OR], 0.57; 95% confidence interval [CI], 0.52–0.62), whereas those admitted in June had 56% lower odds of mortality (OR, 0.44; 95% CI, 0.39–0.49), and those admitted in July had 57% lower odds of mortality (OR, 0.43; 95% CI, 0.39–0.49) compared to patients admitted in April. Compared to the LOS among COVID-19 patients admitted in April, patients admitted in May had an average 4% shorter LOS (adjusted ratio of means, 0.96; 95% CI, 0.94–0.98), whereas patients admitted in June and July had 26% (adjusted ratio of means, 0.74; 95% CI, 0.72–0.76) and 46% (adjusted ratio of means, 0.54; 95% CI, 0.53–0.56) shorter LOS, respectively. The age-stratified GEE analysis revealed that the decrease in mortality was more pronounced in COVID-19 patients aged 60 years or older, and the decrease after June 2020 in LOS was consistent across all age groups. Among patients admitted to an intensive care unit (ICU), the mortality rates were 40.8% in April, 32.9% in May, 27.3% in June, and 27.2% in July (P trend $< .0001$). The LOSs for COVID-19 patients admitted to ICU were 16.6 days (± 14.2) in April, 15.5 days (± 12.8) in May, 12.3 days (± 9.3) in June, and 8.1 days (± 5.7) in July (P trend $< .0001$).

Discussion

In the initial stages of the pandemic in the United States, the patients hospitalized with COVID-19 were mostly older individuals with high comorbidity burden,⁶ but as the pandemic has spread, an increasing number of hospitalizations have been reported among younger individuals.⁷ The decrease in average age and comorbidity status among COVID-19 cases as the pandemic has progressed has also been reflected in our sample of hospitalized patients. Reductions in mortality, as seen in this study, mirror those from other recent studies.^{2,3} We also observed significant reductions in LOS, especially in June and July (vs April); together with mortality reductions, these reductions suggest that the evolving clinical care for hospitalized COVID-19 patients is producing incremental gains in outcomes. The improvements in mortality and LOS were notable for COVID-19 patients admitted to ICUs, reflecting the incremental treatment gains among more severe cases. Several different medical and public health policy factors may have contributed to these meaningful declines in mortality and LOS: improved clinical experience among physicians, better hospital protocols in patient management, more effective treatment options, increased usage of masks and social distancing measures reducing the volume of hospitalization pressure on healthcare systems.⁸

Acknowledgments. We extend our appreciation to Rusha Chaudhuri, Harikumaran R. Dwarakanathan, Aatheep Gurubaran, Joseph Guilfoyle, and Pragma Rai for their assistance with this study.

Financial support. This study was sponsored by Johnson & Johnson.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

1. Coronavirus disease 2019 (COVID-19): cases in US Centers for Disease Control and Prevention website. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>. Published 2020. Accessed March 30, 2021.
2. Harris JE. COVID-19 case mortality rates continue to decline in Florida. *medRxiv* 2020. doi: [10.1101/2020.08.03.20167338](https://doi.org/10.1101/2020.08.03.20167338).
3. Horwitz L, Jones SA, Cerfolio RJ, et al. Trends in COVID-19 risk-adjusted mortality rates in a single health system. *medRxiv* 2020. doi: [10.1101/2020.08.11.20172775](https://doi.org/10.1101/2020.08.11.20172775).
4. Premier Healthcare Database White Paper: data that informs and performs, March 2, 2020. Premier Applied Sciences website. <https://learn.premierinc.com/white-papers/premier-healthcaredatabase-whitepaper>. Published March 2020. Accessed March 30, 2021.
5. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. *Med Care* 1998;36:8–27.
6. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. *Morb Mortal Wkly Rep* 2020;69:458–464.
7. Greene DN, Jackson ML, Hillyard DR, Delgado JC, Schmidt RL. Decreasing median age of COVID-19 cases in the United States: changing epidemiology or changing surveillance? *PLoS One* 2020;15(10):e0240783.
8. VoPham T, Weaver MD, Hart JE, Ton M, White E, Newcomb PA. Effect of social distancing on COVID-19 incidence and mortality in the US. *medRxiv* 2020. doi: [10.1101/2020.06.10.20127589](https://doi.org/10.1101/2020.06.10.20127589).